BRPI0915977A2 - imidazol carboxamidas - Google Patents

imidazol carboxamidas

Info

Publication number
BRPI0915977A2
BRPI0915977A2 BRPI0915977A BRPI0915977A BRPI0915977A2 BR PI0915977 A2 BRPI0915977 A2 BR PI0915977A2 BR PI0915977 A BRPI0915977 A BR PI0915977A BR PI0915977 A BRPI0915977 A BR PI0915977A BR PI0915977 A2 BRPI0915977 A2 BR PI0915977A2
Authority
BR
Brazil
Prior art keywords
imidazole carboxamides
carboxamides
imidazole
Prior art date
Application number
BRPI0915977A
Other languages
English (en)
Portuguese (pt)
Inventor
Khilevich Albert
Liu Bin
Ray Mayhugh Daniel
Zhang Deyi
Michael Schkeryantz Jeffrey
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of BRPI0915977A2 publication Critical patent/BRPI0915977A2/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/91Nitro radicals
    • C07D233/92Nitro radicals attached in position 4 or 5
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Developing Agents For Electrophotography (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
BRPI0915977A 2008-07-18 2009-07-14 imidazol carboxamidas BRPI0915977A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8177408P 2008-07-18 2008-07-18
PCT/US2009/050440 WO2010009062A1 (en) 2008-07-18 2009-07-14 Imidazole carboxamides

Publications (1)

Publication Number Publication Date
BRPI0915977A2 true BRPI0915977A2 (pt) 2018-10-30

Family

ID=41128155

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0915977A BRPI0915977A2 (pt) 2008-07-18 2009-07-14 imidazol carboxamidas

Country Status (19)

Country Link
US (1) US7754742B2 (https=)
EP (1) EP2318375B1 (https=)
JP (1) JP5379227B2 (https=)
KR (1) KR101287713B1 (https=)
CN (1) CN102099344B (https=)
AR (1) AR074631A1 (https=)
BR (1) BRPI0915977A2 (https=)
CA (1) CA2731215C (https=)
CY (1) CY1113315T1 (https=)
DK (1) DK2318375T3 (https=)
EA (1) EA018434B1 (https=)
ES (1) ES2393243T3 (https=)
HR (1) HRP20120830T1 (https=)
MX (1) MX2011000611A (https=)
PL (1) PL2318375T3 (https=)
PT (1) PT2318375E (https=)
SI (1) SI2318375T1 (https=)
TW (1) TW201006801A (https=)
WO (1) WO2010009062A1 (https=)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI417095B (zh) 2006-03-15 2013-12-01 Janssen Pharmaceuticals Inc 1,4-二取代之3-氰基-吡啶酮衍生物及其作為mGluR2-受體之正向異位性調節劑之用途
TW200845978A (en) 2007-03-07 2008-12-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
TW200900065A (en) 2007-03-07 2009-01-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
US8722894B2 (en) 2007-09-14 2014-05-13 Janssen Pharmaceuticals, Inc. 1,3-disubstituted-4-phenyl-1H-pyridin-2-ones
PL2203439T3 (pl) 2007-09-14 2011-06-30 Addex Pharmaceuticals Sa 1',3'-dipodstawione-4-fenylo-3,4,5,6-tetrahydro-2H, 1'H-[1, 4']bipirydynylo-2'-ketony
JP5547194B2 (ja) 2008-09-02 2014-07-09 ジャンセン ファーマシューティカルズ, インコーポレイテッド. 代謝型グルタミン酸受容体の調節因子としての3−アザビシクロ[3.1.0]ヘキシル誘導体
RU2517181C2 (ru) 2008-10-16 2014-05-27 Орто-Макнейл-Янссен Фармасьютикалз, Инк. Производные индола и бензоморфолина в качестве модулятора метаботропных глутаматных рецепторов
MY153913A (en) 2009-05-12 2015-04-15 Janssen Pharmaceuticals Inc 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
CN102439008B (zh) 2009-05-12 2015-04-29 杨森制药有限公司 1,2,4-三唑并[4,3-a]吡啶衍生物及其用于治疗或预防神经和精神病症的用途
MY153912A (en) 2009-05-12 2015-04-15 Janssen Pharmaceuticals Inc 1, 2, 4,-triazolo[4,3-a[pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
EP2661435B1 (en) 2010-11-08 2015-08-19 Janssen Pharmaceuticals, Inc. 1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS
CN103261195B (zh) 2010-11-08 2015-09-02 杨森制药公司 1,2,4-三唑并[4,3-a]吡啶衍生物及其作为MGLUR2受体的正变构调节剂的用途
PL2649069T3 (pl) 2010-11-08 2016-01-29 Janssen Pharmaceuticals Inc Pochodne 1,2,4-triazolo[4,3-a]pirydyny i ich zastosowanie jako dodatnich allosterycznych modulatorów receptorów mGluR2
CN103502218B (zh) * 2011-03-04 2016-08-17 生命科技公司 用于缀合生物分子的化合物和方法
EP2691393B1 (en) 2011-03-31 2016-09-14 Pfizer Inc Novel bicyclic pyridinones
UA110688C2 (uk) 2012-09-21 2016-01-25 Пфайзер Інк. Біциклічні піридинони
US20140206667A1 (en) 2012-11-14 2014-07-24 Michela Gallagher Methods and compositions for treating schizophrenia
JO3368B1 (ar) 2013-06-04 2019-03-13 Janssen Pharmaceutica Nv مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2
JO3367B1 (ar) 2013-09-06 2019-03-13 Janssen Pharmaceutica Nv مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2
HUE053734T2 (hu) 2014-01-21 2021-07-28 Janssen Pharmaceutica Nv 2-es altípusú metabotróp glutamáterg receptor pozitív allosztérikus modulátorait tartalmazó kombinációk és alkalmazásuk
KR20220049612A (ko) 2014-01-21 2022-04-21 얀센 파마슈티카 엔.브이. 대사 조절형 글루탐산 작동성 수용체 제2아형의 양성 알로스테릭 조절제 또는 오르토스테릭 작동제를 포함하는 조합 및 그 용도
MX368391B (es) 2015-02-03 2019-09-30 Pfizer Ciclopropabenzofuranil-piridopirazindionas novedosas.
CN107207449B (zh) * 2015-04-23 2020-11-10 豪夫迈·罗氏有限公司 用于治疗精神障碍的四唑衍生物
CN104788694B (zh) * 2015-04-29 2018-06-08 江苏亚宝绝缘材料股份有限公司 一种超低收缩率的聚酰亚胺薄膜
CN108137566B (zh) 2015-10-06 2021-05-25 豪夫迈·罗氏有限公司 三唑衍生物
EP3411365B1 (en) 2016-02-02 2019-11-20 H. Hoffnabb-La Roche Ag Pyrazol-pyridine derivatives as eaat3 inhibitors
EP3464246B1 (en) 2016-05-27 2020-07-08 H. Hoffnabb-La Roche Ag Pyrazol compounds as eaat3 inhibitors
CN109563049B (zh) 2016-10-14 2022-11-29 豪夫迈·罗氏有限公司 作为eaat3抑制剂的咪唑化合物

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES494769A0 (es) 1979-09-05 1981-07-16 Glaxo Group Ltd Un procedimiento para la pre-paracion de fenoxialcoxifenil- derivados.
US4666928A (en) 1984-08-30 1987-05-19 Merck Frosst Canada, Ind. Propylphenoxy pyridine carboxylates as leukotriene antagonists
DE69210091T2 (de) 1991-05-31 1996-10-02 Sumitomo Pharma Leukotrien-B4-Antagonisten
WO2001056990A2 (en) 2000-02-03 2001-08-09 Eli Lilly And Company Pyridine derivates as potentiators of glutamate receptors
JP2006502143A (ja) * 2002-08-26 2006-01-19 メルク エンド カムパニー インコーポレーテッド 向代謝型グルタミン酸受容体のアセトフェノン増強因子
EP1773792A1 (en) 2004-07-30 2007-04-18 Merck & Co., Inc. Indanone potentiators of metabotropic glutamate receptors
EP1773774A4 (en) * 2004-07-30 2009-12-30 Merck & Co Inc HETEROCYCLIC ACETOPHENONE AMPLIFIERS OF METABOTROPIC GLUTAMATE RECEPTORS
TW200613272A (en) 2004-08-13 2006-05-01 Astrazeneca Ab Isoindolone compounds and their use as metabotropic glutamate receptor potentiators
CN101048157A (zh) 2004-10-25 2007-10-03 默克公司 代谢型谷氨酸受体的杂环二氢茚酮增强剂
ES2333979T3 (es) 2004-11-22 2010-03-03 Eli Lilly And Company Potenciadores de los receptores del glutamato.
KR20070106690A (ko) 2004-12-27 2007-11-05 아스트라제네카 아베 피라졸론 화합물 및 대사성 글루타메이트 수용체길항제로서 그들의 용도
CN101309905A (zh) 2005-08-12 2008-11-19 阿斯利康(瑞典)有限公司 取代的异吲哚酮及其作为代谢型谷氨酸受体增效剂的用途

Also Published As

Publication number Publication date
JP5379227B2 (ja) 2013-12-25
MX2011000611A (es) 2011-03-01
CN102099344B (zh) 2013-10-30
KR101287713B1 (ko) 2013-07-23
CN102099344A (zh) 2011-06-15
CA2731215C (en) 2013-08-27
EP2318375B1 (en) 2012-09-19
SI2318375T1 (sl) 2012-11-30
TW201006801A (en) 2010-02-16
KR20110022676A (ko) 2011-03-07
EA018434B1 (ru) 2013-07-30
WO2010009062A1 (en) 2010-01-21
EP2318375A1 (en) 2011-05-11
ES2393243T3 (es) 2012-12-19
DK2318375T3 (da) 2012-10-08
CY1113315T1 (el) 2016-04-13
AU2009271105A1 (en) 2010-01-21
US7754742B2 (en) 2010-07-13
PT2318375E (pt) 2012-10-22
US20100016373A1 (en) 2010-01-21
HRP20120830T1 (hr) 2012-11-30
PL2318375T3 (pl) 2013-02-28
AR074631A1 (es) 2011-02-02
EA201170227A1 (ru) 2011-06-30
CA2731215A1 (en) 2010-01-21
JP2011528658A (ja) 2011-11-24

Similar Documents

Publication Publication Date Title
BRPI0915977A2 (pt) imidazol carboxamidas
BR112012010502A2 (pt) derivados de benzimidazol-imidazol
EP2303378A4 (en) INTERFACE
PT2813570T (pt) Resumo
BRPI0919116A2 (pt) método
EP2351549A4 (en) INTERCONNECTS
DK2308869T3 (da) Azolforbindelse
BRPI0817609A2 (pt) Derivados de imidazol
PT3045471T (pt) Resumo
BRPI0914743A2 (pt) estrutura
FI20080462A0 (fi) Einespakkaus
DK2313489T3 (da) Fremstillingsmetode
EP2351082A4 (en) METAL-INSULATOR-METAL CAPACITORS
BRPI0914274A2 (pt) plataforma
EP2326553A4 (en) TRIM FLAP
BRPI0818855A2 (pt) Derivados de imidazol
DK2300238T3 (da) Skyggebillede-sikkerhedstræk
BRPI0907963A2 (pt) Derivados de indazola
FI20085672A0 (fi) Säiliö
DK2379722T3 (da) Ekspressionsvektor
BRPI0916597A2 (pt) Método
DE112008004073T8 (de) Tank
FI20085899A0 (fi) Puu-Metalli-komposiittirakenne
DE112009001697A5 (de) Pumpeneinheit
BRPI0818863A2 (pt) Derivados de imidazol

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 9A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2497 DE 13-11-2018 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.